The molecules involved in HIV-1 entry have now been identified making it possible to target this process for strategies to inhibit viral infection. The process requires two molecular entities, a coreceptor that also binds chemokines and a complex formed between the HIV-1 envelope, gp120, and the primary cell receptor, CD4. Antibodies that bind to epitopes involved in the coreceptor interaction should neutralize HIV-1 and therefore be useful for passive immunity to prevent or treat infection. In this project, the investigators will use two strategies to raise such antibodies in mice. The first will be immunization with covalently crosslinked gp120-CD4 complexes to raise monoclonal antibodies against the coreceptor binding site on the viral envelope. The investigators have already shown that these complexes elicit broadly neutralizing responses that interfere in a post-CD4 binding step. The second will be to raise antibodies specific for the viral attachment site on the coreceptors CCR5 and CxCR4. Neutralizing mAbs that block entry processes will be """"""""humanized"""""""" by recombinant DNA methods developed by this group to provide reagents for passive immunotherapy. This approach, which allows the investigators to manipulate specific immunogens in order to obtain the desired responses, will allow them to isolate neutralizing mAbs from mice and to characterize them in less time than it would take to identify, characterize, and isolate the human counterparts.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL059796-03
Application #
6056501
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Project Start
1997-09-30
Project End
2002-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of MD Biotechnology Institute
Department
Type
Organized Research Units
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21202
Gallo, Robert C (2015) Developing a Successful HIV Vaccine. J Infect Dis 212 Suppl 1:S40-1
Fouts, Timothy R; Bagley, Kenneth; Prado, Ilia J et al. (2015) Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A 112:E992-9
Taylor, Brian M; Foulke, J Scott; Flinko, Robin et al. (2008) An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol 82:5460-71
DeVico, Anthony; Fouts, Timothy; Lewis, George K et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104:17477-82
Vu, John R; Fouts, Timothy; Bobb, Katherine et al. (2006) An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro. AIDS Res Hum Retroviruses 22:477-90
Hammonds, Jason; Chen, Xuemin; Ding, Lingmei et al. (2003) Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology 314:636-49
Chow, Yen-Hung; Wei, Olivia L; Phogat, Sanjay et al. (2002) Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry 41:7176-82
Fouts, Timothy; Godfrey, Karla; Bobb, Kathryn et al. (2002) Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 99:11842-7
Devico, Anthony L; Fouts, Timothy R; Shata, Mohamed T et al. (2002) Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20:1968-74
Kamin-Lewis, R; Abdelwahab, S F; Trang, C et al. (2001) Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta. Proc Natl Acad Sci U S A 98:9283-8